Journal of the Neurological Sciences
Volume 223, Issue 2 , Pages 161-166 , 30 August 2004

Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease

  • Makoto Sohmiya

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +81-27-220-8061; fax: +81-27-220-8068.
    • Department of Neurology, Gunma University Graduate School of Medicine, 3-39-22 Showamachi, Maebashi, Gunma 371-8511, Japan
    • ,
  • Makoto Tanaka

      Affiliations

    • Department of Neurology, Gunma University Graduate School of Medicine, 3-39-22 Showamachi, Maebashi, Gunma 371-8511, Japan
    • ,
  • Nyou Wei Tak

      Affiliations

    • Department of Chemistry and Biotechnology, School of Engineering, The University of Tokyo, Tokyo 113-8656, Japan
    • ,
  • Makoto Yanagisawa

      Affiliations

    • Department of Chemistry and Biotechnology, School of Engineering, The University of Tokyo, Tokyo 113-8656, Japan
    • ,
  • Yutaka Tanino

      Affiliations

    • School of Bionics, Tokyo University of Technology, 1404-1 Katakura, Hachioji, Tokyo 192-0982, Japan
    • ,
  • Yoko Suzuki

      Affiliations

    • Department of Neurology, Gunma University Graduate School of Medicine, 3-39-22 Showamachi, Maebashi, Gunma 371-8511, Japan
    • ,
  • Koichi Okamoto

      Affiliations

    • Department of Neurology, Gunma University Graduate School of Medicine, 3-39-22 Showamachi, Maebashi, Gunma 371-8511, Japan
    • ,
  • Yorihiro Yamamoto

      Affiliations

    • School of Bionics, Tokyo University of Technology, 1404-1 Katakura, Hachioji, Tokyo 192-0982, Japan

Received 21 July 2003 ,Revised 20 February 2004 ,Accepted 11 May 2004.

References 

  1. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology. 1996;47:S161–S170
  2. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, et al.  Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 1989;52:1830–1836
  3. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MBH. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 1991;56:978–982
  4. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex deficiency in Parkinson's disease. Lancet. 1989;1:1269
  5. Marttila RJ, Lorentz H, Rinne UK. Oxygen toxicity protecting enzymes in Parkinson's disease. J. Neurol. Sci. 1988;86:321–331
  6. Saggu H, Cooksey J, Dexter D, Wells FR, Lees P, Marsden CD. A selective increase in particulate superoxide dismutase activity in Parkinsonian substantia nigra. J. Neurochem. 1989;53:692–697
  7. Perry TL, Godin DV, Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency?. Neurosci. Lett. 1982;33:305–310
  8. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, et al.  Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 1989;52:381–389
  9. Dexter DT, Holley AE, Flitter WD, Slater TF, Wells FR, Daniel SE, et al.  Increased levels of lipid hydroperoxides in the Parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 1994;9:92–97
  10. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 1996;93:2696–2701
  11. Sanchez-Ramos J, Overvik E, Ames BN. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′ deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration. 1994;3:197–204
  12. Parker W, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 1989;26:719–723
  13. Krige D, Carroll MT, Cooper JM, Marsden CD, Schapira AH. Platelet mitochondrial function in Parkinson's disease. Ann. Neurol. 1992;32:782–788
  14. Benecke R, Strumper P, Weiss H. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain. 1993;116:1451–1463
  15. Bindoff LA, Birch-Machin M, Cartlidge NE, Parker W, Turnbull DM. Mitochondrial function in Parkinson's disease. Lancet. 1989;2:49
  16. Shoffner JM, Watts RL, Juncos JL, Torroni A, Wallace DC. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann. Neurol. 1991;30:332–339
  17. Bindoff LA, Birch-Machin MA, Cartlidge NE, Parker WD, Turnbull DM. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. J. Neurol. Sci. 1991;104:203–208
  18. Nakagawa-Hattori Y, Yoshino H, Kondo T, Mizuno Y, Horai S. Is Parkinson's disease a mitochondrial disorder?. J. Neurol. Sci. 1992;107:29–33
  19. Cardellach F, Marti MJ, Fernandez-Sola J, Marin C, Hoek JB, Tolosa E, et al.  Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. Neurology. 1993;43:2258–2262
  20. Blin O, Desnuelle C, Rascol O, Borg M, Peyro Saint Paul H, Azulay JP, et al.  Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy. J. Neurol. Sci. 1994;125:95–101
  21. Barroso N, Campos Y, Huertas R, Esteban J, Molina JA, Alonso A, et al.  Respiratory chain enzyme activities in lymphocytes from untreated patients with Parkinson disease. Clin. Chem. 1993;39:667–669
  22. Bravi D, Anderson JJ, Dagani F, Davis TL, Ferrari R, Gillespie M, et al.  Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease. Mov. Disord. 1992;7:228–231
  23. DiDonato S, Zeviani M, Giovannini P, Savarese N, Rimoldi M, Mariotti C, et al.  Respiratory chain and mitochondrial DNA in muscle and brain in Parkinson's disease patients. Neurology. 1993;43:2262–2268
  24. Martin MA, Molina JA, Jimenez-Jimenez FJ, Benito-Leon J, Orti-Pareja M, Campos Y, et al.  Respiratory-chain enzyme activities in isolated mitochondria of lymphocytes from untreated Parkinson's disease patients. Neurology. 1996;46:1343–1346
  25. Molina JA, Ruiz-Pesini E, Jimenez-Jimenez FJ, Lopez-Perez MJ, Alvarez E, Berbel A, et al.  Respiratory chain enzyme activities in spermatozoa from untreated Parkinson's disease patients. J. Neural Transm. 1999;106:919–924
  26. Ahlskog JE, Uitti RJ, Low PA, Tyce GM, Nickander KK, Petersen RC, et al.  No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Mov. Disord. 1995;10:566–573
  27. Fernandez-Calle P, Molina JA, Jimenez-Jimenez FJ, Vazquez A, Pondal M, Garcia-Ruiz PJ, et al.  Serum levels of alpha-tocopherol (vitamin E) in Parkinson's disease. Neurology. 1992;42:1064–1066
  28. Foy CJ, Passmore AP, Vahidassr MD, Young IS, Lawson JT. Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease. Q. J. Med. 1999;92:39–45
  29. Jimenez-Jimenez FJ, Molina JA, de Bustos F, Garcia-Redondo A, Gomez-Escalonilla C, Martinez-Salio A, et al.  Serum levels of coenzyme Q10 in patients with Parkinson's disease. J. Neural Transm. 2000;107:177–181
  30. Jimenez-Jimenez FJ, Molina JA, Fernandez-Calle P, Vazquez A, Cabrera-Valdivia F, Catalan MJ, et al.  Serum levels of beta-carotene and other carotenoids in Parkinson's disease. Neurosci. Lett. 1993;157:103–106
  31. Yamamoto Y, Kawamura M, Tatsuno K, Yamashita S, Niki E, Naito C. Formation of lipid hydroperoxides in the cupric ion-induced oxidation of plasma and low density lipoprotein. In:  Davies KJA editors. Oxidative damage and repair. London: Pergamon; 1991;p. 287–291
  32. Yamashita S, Yamamoto Y. Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stress. Anal. Biochem. 1997;250:66–73
  33. Yamamoto Y, Yamashita S, Fujisawa A, Kokura S, Yoshikawa T. Oxidative stress in patients with hepatitis, cirrhosis and hepatoma evaluated by plasma antioxidants. Biochem. Biophys. Res. Commun. 1998;247:166–170
  34. Hara K, Yamashita S, Fujisawa A, Ishiwa S, Ogawa T, Yamamoto Y. Oxidative stress in newborn infants with and without asphyxia as measured by plasma antioxidants and free fatty acid. Biochem. Biophys. Res. Commun. 1999;257:244–248
  35. Yamamoto Y, Yamashita S. Plasma ubiquinone and ubiquinol ratio in patients with hepatitis, cirrhosis, and hepatoma, and in patients treated with percutaneous transluminal coronary reperfusion. BioFactors. 1999;9:241–246
  36. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann. Neurol. 1992;32:S125–S127
  37. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–944
  38. Hoehn MH, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17:427–442
  39. Fahn S, Elton R. Members of the UPDRS development committee. Unified Parkinson's Disease rating scale. In:  Fahn S,  Marsden CD,  Calne DB,  Goldsetin M editor. Recent developments in Parkinson's disease. vol. 2:Florham Park (NJ): Macmillan Healthcare Information; 1987;p. 153–164
  40. Yamamoto Y, Ames BN. Detection of lipid hydroperoxides and hydrogen peroxide at picomole levels by an HPLC and isoluminol chemiluminescence assay. Free Radic. Biol. Med. 1987;3:359–361
  41. Molina JA, de Bustos F, Jimenez-Jimenez FJ, Benito-Leon J, Orti-Pareja M, Gasalla T, et al.  Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Parkinson's disease. J. Neural Transm. 1997;104:1287–1293
  42. Konings CH, Kuiper MA, Teerlink T, Mulder C, Scheltens P, Wolters EC. Normal cerebrospinal fluid glutathione concentrations in Parkinson's disease, Alzheimer's disease and multiple system atrophy. J. Neurol. Sci. 1999;168:112–115
  43. Abe T, Isobe C, Murata T, Sato C, Tohgi H. Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease. Neurosci. Lett. 2003;336:105–108
  44. Kikuchi A, Takeda A, Onodera H, Kimpara T, Hisanaga K, Sato N, et al.  Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol. Dis. 2002;9:244–248
  45. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, et al.  Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 2002;59:1541–1550
  46. Shults CW, Haas RH, Passov D, Beal MF. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann. Neurol. 1997;42:261–264
  47. Shults CW, Beal MF, Fontaine D, Nakano K, Haas RH. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology. 1998;50:793–795
  48. Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. U. S. A. 1998;95:8892–8897

PII: S0022-510X(04)00166-2

doi: 10.1016/j.jns.2004.05.007

Journal of the Neurological Sciences
Volume 223, Issue 2 , Pages 161-166 , 30 August 2004

Article Tools

* Image Usage & Resolution